Cancer Institute NSW has awarded a Translational Program Grant to an impressive team of experienced laboratory and clinical researchers in pancreas cancer, coordinated by Chief Investigator Professor David Goldstein. The team is seeking to develop better targeted treatment options for pancreatic cancer – and ultimately, improve outcomes for people affected.

View the "Demystifying the Molecular Tumour Board" Masterclass publication and webinar recordings

The first patient has been enrolled into the ‘ASPiRATION’ Study. The study is looking at the impact and value of comprehensive genomic profiling (CGP), precision medicine and personalised healthcare (PHC) in newly diagnosed metastatic, non-squamous, non-small cell lung cancer patients.

3000 patients enrolled onto the Molecular Screening and Therapeutics (MoST) program, 1000 people have enrolled in the Genetic Cancer Risk in the Young (RisC) study and 95 people have joined the Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+) - great news for cancer research.

Learn how members of a Molecular Tumour Board (MTB) come together to discuss and interpret tumour molecular profiles in the clinical context, recommending therapeutic strategies for the care of patients with cancer. 4 webinars on 29th Oct, 5th, 12th and 19th Nov 2020, 4 - 5pm

The cells of the human body are constantly dividing, and each time need to copy a three billion-letter DNA code with high precision to ensure cell survival. The same is not true for cancers, researchers have discovered.

Professor David Thomas provides a glimpse of what the future of cancer research could look like.

Roche Australia, in partnership with the Australian Government announced a jointly funded a genomic profiling research project called ‘ASPiRATION’ for 1,000 Australians with newly diagnosed metastatic, non-squamous, non-small cell lung cancer.

Neglected Cancers Awareness Week is an important opportunity to call on government, corporations and the community at large to place a greater focus on less common, but high-mortality cancers.

An innovative suite of clinical trials, matching therapies with Individuals on the basis of genetic information, could one day hold the key to rare and uncommon cancers and give hope to patients who have exhausted other treatment options.